Kantar Health Blog

  • Neesha Suvarna
    Oncology Conference Insight: ASCO GI 2014 --- Hepatocellular carcinoma (HCC) is a particularly challenging disease. Surgery remains the only curative strategy for patients with HCC, however not all patients are eligible for surgery. The approval of Nexavar® (sorafenib, Bayer/Onyx/Amgen) revolutionized HCC, providing a targeted therapy option for patients with HCC and an advance over de facto standard doxorubicin. The enthusiasm for Nexavar is dampened by the fact that not all patients may be eligible for Nexavar treatment due to poor liver function, and options remain limited for patients whose disease progresses.
    Continue Reading > | Go comment! | Share
  • I-SPY 2 Graduates its First Experimental Regimen

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- The I-SPY 2 trial is an innovative “find a winner” trial that aims to address some of these challenges by screening a number of different novel experimental agents in the neoadjuvant setting in combination with a standard chemotherapy regimen of paclitaxel followed by AC compared to standard chemotherapy alone. In this novel trial design, the randomization of patients to treatment arms is adaptive, with randomization probabilities continuing to be updated as the trial progressed.
    Continue Reading > | Go comment! | Share
  • Anastrozole: a new option for breast cancer chemoprevention?

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- There are a variety of known risk factors for developing breast cancer, such as obesity, nulliparity, and age at time of menarche and menopause. For patients with a particularly high risk of developing breast cancer, including those who have a family history of the disease or have tested positive for deleterious BRCA1 or BRCA2 mutations, there are several options available for risk reduction. Currently, two hormonal agents, tamoxifen and raloxifene, are FDA approved to reduce the risk of breast cancer in patients at high risk of developing the disease.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- Endocrine therapy is a mainstay of therapy for breast cancer patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease, with use in the adjuvant setting for early stage disease as well as in the metastatic setting. In the first-line metastatic setting, aromatase inhibitors (AI) can offer clinical benefit in post-menopausal ER+/PR+ patients, with progression-free survival (PFS) in clinical trials ranging from eight to 10 months.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2013 --- Today, on the final day of the annual meeting of the American Society of Hematology (ASH), Richard Furman presented exciting results from a planned interim analysis of a Phase III, randomized double-blind, placebo-controlled study evaluating efficacy and safety of idelalisib (GS-1101, Gilead Sciences) and Rituxan® (rituximab, Genentech/Roche) for previously-treated patients with chronic lymphocytic leukemia (CLL).
    Continue Reading > | Go comment! | Share